Mallinckrodt Inc Drug Patent Portfolio
Mallinckrodt Inc owns 1 orange book drug protected by 13 US patents Given below is the list of Mallinckrodt Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8658631 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
US8741885 | Gastric retentive extended release pharmaceutical compositions | 16 May, 2032 | Active |
US8992975 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
US9050335 | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia | 16 May, 2032 | Active |
US9468636 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia | 16 May, 2032 | Active |
US8597681 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | 21 Dec, 2030 | Active |
US8980319 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | 21 Dec, 2030 | Active |
US8377453 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 19 Nov, 2029 | Active |
US8372432 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
US8394408 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
US8668929 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic | 11 Mar, 2029 | Active |
US7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | 01 Jun, 2027 | Active |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | 20 Jun, 2020 | Expired |
Latest Legal Activities on Mallinckrodt Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mallinckrodt Inc.
Activity | Date | Patent Number |
---|---|---|
Expire Patent
Critical
| 14 Aug, 2023 | US7976870 |
Maintenance Fee Reminder Mailed
Critical
| 27 Feb, 2023 | US7976870 |
Expire Patent
Critical
| 10 Jan, 2022 | US8597681 (Litigated) |
Maintenance Fee Reminder Mailed
Critical
| 26 Jul, 2021 | US8597681 (Litigated) |
Expire Patent
Critical
| 19 Apr, 2021 | US8394408 |
Expire Patent
Critical
| 29 Mar, 2021 | US8377453 |
Expire Patent
Critical
| 22 Mar, 2021 | US8372432 |
Expire Patent
Critical
| 23 Nov, 2020 | US9468636 |
Maintenance Fee Reminder Mailed
Critical
| 02 Nov, 2020 | US8394408 |
Maintenance Fee Reminder Mailed
Critical
| 12 Oct, 2020 | US8377453 |
Maintenance Fee Reminder Mailed
Critical
| 05 Oct, 2020 | US8372432 |
Maintenance Fee Reminder Mailed
Critical
| 08 Jun, 2020 | US9468636 |
Expire Patent
Critical
| 15 Jul, 2019 | US9050335 |
Maintenance Fee Reminder Mailed
Critical
| 28 Jan, 2019 | US9050335 |
Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jan, 2019 | US7976870 |
Mallinckrodt Inc's Family Patents
Mallinckrodt Inc drugs have patent protection in a total of 13 countries. It has a significant patent presence in the US with 67.6% of its patents being US patents. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Mallinckrodt Inc Drug List
Given below is the complete list of Mallinckrodt Inc's drugs and the patents protecting them.
1. Xartemis Xr
Xartemis Xr is protected by 13 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8658631 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(7 years from now)
| Active |
US8741885 | Gastric retentive extended release pharmaceutical compositions |
16 May, 2032
(7 years from now)
| Active |
US8992975 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(7 years from now)
| Active |
US9050335 | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
16 May, 2032
(7 years from now)
| Active |
US9468636 | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
16 May, 2032
(7 years from now)
| Active |
US8597681 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
21 Dec, 2030
(6 years from now)
| Active |
US8980319 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
21 Dec, 2030
(6 years from now)
| Active |
US8377453 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
19 Nov, 2029
(5 years from now)
| Active |
US8372432 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(4 years from now)
| Active |
US8394408 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(4 years from now)
| Active |
US8668929 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
11 Mar, 2029
(4 years from now)
| Active |
US7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
01 Jun, 2027
(2 years from now)
| Active |
US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xartemis Xr's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List